{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030944","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.053535+00:00","generated_at":"2026-06-22T03:32:58.390828+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Processa: PCS12852 Phase 2A improves gastric emptying (p<0.10); nine-month net loss $14.4M","bullets":["PCS12852 Phase 2A: GEBT showed gastric emptying improvement for 0.5mg dose vs placebo (p<0.10); mild-to-moderate AEs, no serious events.","Net loss for nine months ended Sep 30, 2022: $14.4M ($0.90/share) vs $8.2M ($0.54/share) YoY.","Cash at Sep 30, 2022: $9.1M; expected to fund operations into Q3 2023.","R&D expenses rose to $8.3M (up $3.5M) due to ongoing clinical trials; G&A $6.1M (up from $3.4M).","Plans: Phase 2B trial for PCS12852 in 2023; NGC (PCS6422+capecitabine) Phase 2B planned after FDA meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030944","json":"https://secwatch.observer/filing/0001493152-22-030944.json","markdown":"https://secwatch.observer/filing/0001493152-22-030944.md","text":"https://secwatch.observer/filing/0001493152-22-030944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/0001493152-22-030944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:32:58.390828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc53f39cc9d57b038b4f03e7b3467d61d79988e3","claim":"Processa Pharmaceuticals, Inc. reported for the nine months ended September 30, 2022 results: net income $14.4 million, EPS $0.90 per share.","evidence_excerpt":"Our net loss for the nine months ended September 30, 2022, was $14.4 million or $0.90 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/0001493152-22-030944-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the nine months ended September 30, 2022"},{"label":"Net income","value":"$14.4 million"},{"label":"EPS","value":"$0.90 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}